Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | LSS | P48449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25565768 | 0.98 | CHRM2 (0.39) | CHRM2KDM4EALDH1A1PIK3CDSLC6A2 | |
| SCHEMBL25565751 | 0.95 | KDM4E (0.38) | CHRM2KDM4EALDH1A1PIK3CDSLC6A2 | |
| SCHEMBL25569588 | 0.90 | KDM4E (0.32) | CHRM2KDM4E | |
| SCHEMBL16130295 | 0.87 | PIK3CD (0.36) | CHRM2KDM4EPIK3CD | |
| SCHEMBL25075497 | 0.86 | PIK3CD (0.43) | CHRM2KDM4EALDH1A1PIK3CD | |
| SCHEMBL25963452 | 0.86 | HTR1D (0.36) | CHRM2KDM4EALDH1A1PIK3CDSIGMAR1 | |
| SCHEMBL18512355 | 0.84 | SIGMAR1 (0.37) | CHRM2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL15511370 | 0.84 | KDM4E (0.35) | KDM4EALDH1A1PIK3CD | |
| SCHEMBL10081279 | 0.83 | ALDH1A1 (0.48) | KDM4EALDH1A1 | |
| SCHEMBL25075500 | 0.82 | ALDH1A1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TIBA BIOTECH LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | TIBA BIOTECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | TIBA BIOTECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | POLN, TLR9, TSG101 | CHRM2 4667/4885KDM4E 4832/4885ALDH1A1 3979/4885 |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TLR9, TLR3, TSG101 | CHRM2 4752/4885KDM4E 4820/4885ALDH1A1 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.